Dr. Mitchell Boxer MD
Assistant Clinical Professor, Albert Einstein College of Medicine
Member of the Healthcare Council
Council Member Biography
Mitchell Boxer, MD, is Director of the Adult Allergy Section at Long Island Jewish Medical Center and Assistant Clinical Professor at Albert Einstein Medical College. He also runs his own private practice. Dr. Boxer completed his fellowship at Northwestern University Medical College and has expertise in a wide range of allergic and immunologic diseases, including asthma, chronic sinusitis, allergic rhinitis, drug allergies and immunoglobulin deficiencies (This is me - Update Profile)
Employment History
- 1988 - Unspecified
- Assistant Clinical Professor, Albert Einstein College of Medicine
- 1987 - Unspecified
- Director of Adult Allergy Section, LONG ISLAND JEWISH MEDICAL CENTER
GLG NewsSM Analyses by Mitchell Boxer(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
August 30, 2007
Collegium Pharmaceutical provides update on development of its nasal inhaled steroid for allergic rhinitis | www.pipelinereview.com
A new nasal corticosteroid being released by another pharmaceutical company
-
August 30, 2007
New antihistamine gets FDA green light.(RX CARE)(Levocetirizine (Xyzal) by UCB Inc. and Sanofi-Aventis ) | www.therapeuticsdaily.com
Zyrtec will soon be available over the counter and this new product will attempt to keep the antihistamine market share for Sanofi-Aventis - although Zyrtec is presently manufactured by Pfizer. The antihistamine market is quite large and the OTC versus prescription situation is making this problematic for both physicians, patients and insurance companies.
-
intranasal antibiotics for chronic sinusitis
April 23, 2007
FDA Approves Fast Track Designation for Naryx Pharma’s Product for Chronic Sinusitis | www.naryxpharma.com
I have not found nebulized antibiotic therapy to be of great success in patients with chronic sinusitis. There are already a few pharmacies that have formulated an array of nebulized antibiotics and I have tried them in a few patients with no success.
-
February 27, 2007
FDA Orders Black Box Anaphylaxis Warning for Omalizumab (Xolair) | www.medpagetoday.com
There is a concern about anaphylaxis secondary to Xolair administration and this may result in longer waiting times after the administration of the drug.
-
February 13, 2007
Patient Treatment Completed in Phase 3 Trial of C1-Esterase Inhibitor in Hereditary Angioedema | www.ptcommunity.com
HAE is a rare but potentially life threatening immunologic disease. If c1 esterase inhibitor is found to be effective in preventing exacerbations of HAE than this novel treatment will have a great impact on the lives of those affected and will undoubtedly replace the present treatments such as androgens in preventing attacks. It would be of interest in seeing how the European community is presently using this replacement therapy.
Leading institutions connect with Mitchell Boxer through GLG
GLG Study Groups with Mitchell Boxer(?)
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 766 |
| Pulmonologists (US) | 759 |
| Physicians who Treat Asthma (US) | 610 |
| Allergists (US) | 419 |
| Immunologists (US) | 384 |
GLG Live Meetings with Mitchell Boxer(?)
Mitchell Boxer has not participated in any GLG Live Meetings.